Physician profile
John D Green
NPI 1659486900
$877,957.91
in general payments reported to CMS, 2019-2025
11 companies · $156K in 2025
The $156K reported for 2025 was more than what 99% of Obstetrics & Gynecology providers received nationally (typical 2025 total: $158).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $85K · 2020: $125K · 2021: $111K · 2022: $126K · 2023: $129K · 2024: $146K · 2025: $156K.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Royalty Or License: $429K · Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program: $2,750 · Food and Beverage: $57.93 · Education: $35.62.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Royalty Or License | $429,065.00 |
| Compensation For Serving As Faculty Or As A Speaker For A Medical Education Program | $2,750.00 |
| Food and Beverage | $57.93 |
| Education | $35.62 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic, INC. | $665,701.00 | 2021-2025 | |
| Medtronic USA, INC. | $209,201.26 | 2019-2020 | |
| Organon LLC | $2,750.00 | 2024 | |
| Astellas Pharma US INC | $114.12 | 2022-2023 | Veozah |
| Avion Pharmaceuticals | $45.97 | 2022 | |
| Abbvie INC. | $43.29 | 2022-2023 | |
| Sumitomo Pharma America, INC. | $35.62 | 2024 | Myfembree |
| Xeris Pharmaceuticals, INC. | $24.51 | 2021 | |
| Novo Nordisk INC | $17.97 | 2025 | Ozempic, Rybelsus |
| Merck Sharp & Dohme LLC | $17.35 | 2021 | |
| Mayne Pharma Commercial LLC | $6.82 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw John Green listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.